Advertisement
Screener

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Stock Split Ratio

2.8 / 5 stars · 68/120 Roast Me

TONIX PHARMACEUTICALS HOLDING CORP. Stock Split Ratio

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Stock Split Ratio of 10.00% for the 0-month period ending 2019-11-01, per its 10-K filed 2020-03-24.

Discontinued › Notes › Equity › Stockholders' Equity Note

us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2020-03-24

  • TONIX PHARMACEUTICALS HOLDING CORP. stockholders' equity note, stock split, conversion ratio for fiscal 2018 was 10.00%.
Period endStockholders' Equity Note, Stock Split, Conversion Ratio 0 monthStockholders' Equity Note, Stock Split, Conversion Ratio 12 month
2019-11-0110.00%
10-K · filed 2020-03-24
2018-12-3110.00%
10-K · filed 2019-03-18
2018-11-2810.00%
10-K · filed 2020-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Annexon, Inc. (ANNX)United States$0.147B-4.22
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91